Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation. / Nielsen, Karin M.; Jørgensen, Nis P.; Kyneb, Majbritt H.; Borghammer, Per; Meyer, Rikke L.; Thomsen, Trine R.; Bender, Dirk; Jensen, Svend B.; Nielsen, Ole L.; Alstrup, Aage K.O.

I: Journal of Labelled Compounds and Radiopharmaceuticals, Bind 61, Nr. 10, 2018, s. 780-795.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Nielsen, KM, Jørgensen, NP, Kyneb, MH, Borghammer, P, Meyer, RL, Thomsen, TR, Bender, D, Jensen, SB, Nielsen, OL & Alstrup, AKO 2018, 'Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation', Journal of Labelled Compounds and Radiopharmaceuticals, bind 61, nr. 10, s. 780-795. https://doi.org/10.1002/jlcr.3640

APA

Nielsen, K. M., Jørgensen, N. P., Kyneb, M. H., Borghammer, P., Meyer, R. L., Thomsen, T. R., Bender, D., Jensen, S. B., Nielsen, O. L., & Alstrup, A. K. O. (2018). Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 61(10), 780-795. https://doi.org/10.1002/jlcr.3640

Vancouver

Nielsen KM, Jørgensen NP, Kyneb MH, Borghammer P, Meyer RL, Thomsen TR o.a. Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation. Journal of Labelled Compounds and Radiopharmaceuticals. 2018;61(10):780-795. https://doi.org/10.1002/jlcr.3640

Author

Nielsen, Karin M. ; Jørgensen, Nis P. ; Kyneb, Majbritt H. ; Borghammer, Per ; Meyer, Rikke L. ; Thomsen, Trine R. ; Bender, Dirk ; Jensen, Svend B. ; Nielsen, Ole L. ; Alstrup, Aage K.O. / Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation. I: Journal of Labelled Compounds and Radiopharmaceuticals. 2018 ; Bind 61, Nr. 10. s. 780-795.

Bibtex

@article{70c2a0347c1049eebf428630f5a908d5,
title = "Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation",
abstract = "The development of bacteria-specific infection radiotracers is of considerable interest to improve diagnostic accuracy and enabling therapy monitoring. The aim of this study was to determine if the previously reported radiolabelled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) conjugated peptide [68Ga]Ga-DOTA-K-A9 could detect a staphylococcal infection in vivo and distinguish it from aseptic inflammation. An optimized [68Ga]Ga-DOTA-K-A9 synthesis omitting the use of acetone was developed, yielding 93 ± 0.9% radiochemical purity. The in vivo infection binding specificity of [68Ga]Ga-DOTA-K-A9 was evaluated by micro positron emission tomography/magnetic resonance imaging of 15 mice with either subcutaneous Staphylococcus aureus infection or turpentine-induced inflammation and compared with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). The scans showed that [68Ga]Ga-DOTA-K-A9 accumulated in all the infected mice at injected doses ≥3.6 MBq. However, the tracer was not found to be selective towards infection, since the [68Ga]Ga-DOTA-K-A9 also accumulated in mice with inflammation. In a concurrent in vitro binding evaluation performed with a 5-carboxytetramethylrhodamine (TAMRA) fluorescence analogue of the peptide, TAMRA-K-A9, the microscopy results suggested that TAMRA-K-A9 bound to an intracellular epitope and therefore preferentially targeted dead bacteria. Thus, the [68Ga]Ga-DOTA-K-A9 uptake observed in vivo is presumably a combination of local hyperemia, vascular leakiness and/or binding to an epitope present in dead bacteria.",
keywords = "bacterial infection, fluorescence, gallium-68, murine models, PET, S aureus, [Ga]Ga-DOTA-K-A9",
author = "Nielsen, {Karin M.} and J{\o}rgensen, {Nis P.} and Kyneb, {Majbritt H.} and Per Borghammer and Meyer, {Rikke L.} and Thomsen, {Trine R.} and Dirk Bender and Jensen, {Svend B.} and Nielsen, {Ole L.} and Alstrup, {Aage K.O.}",
year = "2018",
doi = "10.1002/jlcr.3640",
language = "English",
volume = "61",
pages = "780--795",
journal = "Journal of Labelled Compounds and Radiopharmaceuticals",
issn = "0362-4803",
publisher = "JohnWiley & Sons Ltd",
number = "10",

}

RIS

TY - JOUR

T1 - Preclinical evaluation of potential infection-imaging probe [68Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation

AU - Nielsen, Karin M.

AU - Jørgensen, Nis P.

AU - Kyneb, Majbritt H.

AU - Borghammer, Per

AU - Meyer, Rikke L.

AU - Thomsen, Trine R.

AU - Bender, Dirk

AU - Jensen, Svend B.

AU - Nielsen, Ole L.

AU - Alstrup, Aage K.O.

PY - 2018

Y1 - 2018

N2 - The development of bacteria-specific infection radiotracers is of considerable interest to improve diagnostic accuracy and enabling therapy monitoring. The aim of this study was to determine if the previously reported radiolabelled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) conjugated peptide [68Ga]Ga-DOTA-K-A9 could detect a staphylococcal infection in vivo and distinguish it from aseptic inflammation. An optimized [68Ga]Ga-DOTA-K-A9 synthesis omitting the use of acetone was developed, yielding 93 ± 0.9% radiochemical purity. The in vivo infection binding specificity of [68Ga]Ga-DOTA-K-A9 was evaluated by micro positron emission tomography/magnetic resonance imaging of 15 mice with either subcutaneous Staphylococcus aureus infection or turpentine-induced inflammation and compared with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). The scans showed that [68Ga]Ga-DOTA-K-A9 accumulated in all the infected mice at injected doses ≥3.6 MBq. However, the tracer was not found to be selective towards infection, since the [68Ga]Ga-DOTA-K-A9 also accumulated in mice with inflammation. In a concurrent in vitro binding evaluation performed with a 5-carboxytetramethylrhodamine (TAMRA) fluorescence analogue of the peptide, TAMRA-K-A9, the microscopy results suggested that TAMRA-K-A9 bound to an intracellular epitope and therefore preferentially targeted dead bacteria. Thus, the [68Ga]Ga-DOTA-K-A9 uptake observed in vivo is presumably a combination of local hyperemia, vascular leakiness and/or binding to an epitope present in dead bacteria.

AB - The development of bacteria-specific infection radiotracers is of considerable interest to improve diagnostic accuracy and enabling therapy monitoring. The aim of this study was to determine if the previously reported radiolabelled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) conjugated peptide [68Ga]Ga-DOTA-K-A9 could detect a staphylococcal infection in vivo and distinguish it from aseptic inflammation. An optimized [68Ga]Ga-DOTA-K-A9 synthesis omitting the use of acetone was developed, yielding 93 ± 0.9% radiochemical purity. The in vivo infection binding specificity of [68Ga]Ga-DOTA-K-A9 was evaluated by micro positron emission tomography/magnetic resonance imaging of 15 mice with either subcutaneous Staphylococcus aureus infection or turpentine-induced inflammation and compared with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG). The scans showed that [68Ga]Ga-DOTA-K-A9 accumulated in all the infected mice at injected doses ≥3.6 MBq. However, the tracer was not found to be selective towards infection, since the [68Ga]Ga-DOTA-K-A9 also accumulated in mice with inflammation. In a concurrent in vitro binding evaluation performed with a 5-carboxytetramethylrhodamine (TAMRA) fluorescence analogue of the peptide, TAMRA-K-A9, the microscopy results suggested that TAMRA-K-A9 bound to an intracellular epitope and therefore preferentially targeted dead bacteria. Thus, the [68Ga]Ga-DOTA-K-A9 uptake observed in vivo is presumably a combination of local hyperemia, vascular leakiness and/or binding to an epitope present in dead bacteria.

KW - bacterial infection

KW - fluorescence

KW - gallium-68

KW - murine models

KW - PET

KW - S aureus

KW - [Ga]Ga-DOTA-K-A9

U2 - 10.1002/jlcr.3640

DO - 10.1002/jlcr.3640

M3 - Journal article

C2 - 29790580

AN - SCOPUS:85051436957

VL - 61

SP - 780

EP - 795

JO - Journal of Labelled Compounds and Radiopharmaceuticals

JF - Journal of Labelled Compounds and Radiopharmaceuticals

SN - 0362-4803

IS - 10

ER -

ID: 201908435